secwatch.observer — SEC 8-K summary
======================================

Issuer:     CUMBERLAND PHARMACEUTICALS INC (CPIX)
CIK:        0001087294
Form:       8-K
Filed at:   2022-12-12T23:59:59+00:00
Accession:  0001628280-22-031743
Event type: regulatory
Sentiment:  positive
Materiality: 0.50
Item codes: 8.01
LLM model:  deepseek-v4-flash:cloud@v2

FDA approves new manufacturing site for Cumberland's Sancuso; $1M milestone due
-------------------------------------------------------------------------------

- FDA approved Kindeva as new manufacturing and packaging site for Sancuso on Dec. 6, 2022.
- Cumberland acquired U.S. rights to Sancuso in Jan. 2022; Kyowa Kirin led the FDA submission.
- Cumberland will pay Kyowa Kirin a $1 million milestone payment following the approval.
- Sancuso is the first FDA-approved transdermal patch for chemotherapy-induced nausea/vomiting.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1087294/000162828022031743/0001628280-22-031743-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1087294/000162828022031743/cpix-20221206.htm
  HTML page:      https://secwatch.observer/filing/0001628280-22-031743

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer